Saturday 17 October 2026 Export HAE’s income statement to Excel — free account

Haemonetics Corporation

Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025. In the quarter to June 2026, revenue grew 5.60%, EPS grew 2.86%, free cash flow grew 220.4% and total debt rose 27.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

118.28 3.01 −2.48%

Follow HAE

Alert me

Market cap: $5.5B
P/E: 57.7×
Fwd P/E: 18.0×
Dividend yield: —
F-score: 6/9
Altman Z: 2.21
Beneish M: −2.81
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.10

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	1	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 1.59%

Capital & Financial Ratios $m

Market Cap 5,520.00

Revenue 1,352.01

Net Income 96.29

Free Cash Flow 292.53

Net Debt 945.82

Current Ratio 3.08

Debt/Equity 1.40

P/E ratio 57.70

Fwd P/E 18.00

P/S ratio 3.97

P/B ratio 6.41

Past 5Y EPS Growth 5.75%

This Y EPS Growth 7.12%

Next Y EPS Growth 9.50%

Next Y revenue growth 6.29%

Next 5Y EPS Growth 10.25%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 57.34%

10-year low 10-year high

P/S against its own 10 years 69.63%

10-year low 10-year high

P/B against its own 10 years 73.46%

10-year low 10-year high

EV/Sales against its own 10 years 73.94%

10-year low 10-year high

EV/FCF against its own 10 years 13.09%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2029	Powerpack
2028	Powerpack
2027	Powerpack
2026	Powerpack
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2024	2025	2026	Q'26
Cash	179	307	245	223
Receivables	207	203	217	216
Inventory	317	365	306	307
Other	—	—	—	—
	769	935	835	811

	2024	2025	2026	Q'26
Payables	73	67	51	56
ST’ Debt	—	—	—	—
Other	136	148	158	164
	300	578	283	263

Compound Annual Growth %

	10y	5y	3y
Sales	3.91%	8.91%	4.51%
Cash Flow	9.18%	21.93%	2.40%
Earnings	0.00%	4.13%	(5.53%)
Book Value	0.99%	1.71%	(0.89%)

Revenue $m

	Jun	Sep	Dec	Mar	Year
’26	339	—	—	—	—
’26	321	327	339	346	1,334
’25	336	346	349	331	1,361
’24	311	318	336	343	1,309
’23	261	297	305	304	1,169
’22	229	240	260	265	993
’21	196	209	240	225	870

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	52	—	—	—	—
’26	17	111	94	71	293
’25	(27)	49	44	117	182
’24	19	99	(1)	64	182
’23	42	87	64	80	273
’22	(2)	43	62	68	172
’21	12	29	66	2	109

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Jun	Sep	Dec	Mar	Year
’26	45	—	—	—	—
’26	14	106	88	54	262
’25	(13)	40	35	103	166
’24	12	91	(15)	58	145
’23	(3)	58	48	(20)	83
’22	(15)	23	36	34	78
’21	5	21	57	(9)	74

Fiscal quarters ending in the months shown.

EPS $

	Jun	Sep	Dec	Mar	Year
’26	0.72	—	—	—	—
’26	0.70	0.81	0.95	(0.44)	2.05
’25	0.74	0.66	0.74	1.17	3.31
’24	0.80	0.48	0.61	0.40	2.29
’23	0.38	0.64	0.64	0.57	2.24
’22	(0.09)	0.29	0.45	0.19	0.84
’21	0.21	0.94	0.62	(0.22)	1.55

Fiscal quarters ending in the months shown.

Group	Line	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026	2027e
Price, $
Price, $	Low	36.44	60.51	80.24	63.41	49.26	43.50	72.26	70.25	47.32	51.00	Analyst estimates 2027–2029 Powerpack
	High	58.99	117.56	140.36	126.74	142.11	86.58	95.26	97.97	87.32	123.77
People
People	Employees	3,107	3,136	3,216	3,004	2,708	2,821	3,034	3,657	3,023	3,009
	Revenue/emp, $m	0.29	0.29	0.30	0.33	0.32	0.35	0.39	0.36	0.45	0.44
Income, $m
Income, $m	Revenue	886	904	968	988	870	993	1,169	1,309	1,361	1,334
	Gross margin, %	42.71	45.57	43.15	49.02	45.70	50.90	52.63	52.83	55.04	59.04
	EBT	(27)	60	74	87	73	64	141	152	212	128
	EBT margin, %	(3.10)	6.60	7.61	8.82	8.38	6.41	12.10	11.60	15.58	9.60
	Net income	(26)	46	55	77	79	43	115	118	168	97
	Depreciation	90	89	109	111	85	101	93	101	131	118
Per share, $
Per share, $	Revenue	17.20	17.13	18.78	19.50	17.17	19.46	23.01	25.82	27.04	28.28
	Earnings	(0.51)	0.85	1.07	1.51	1.57	0.84	2.24	2.32	3.33	2.05
	Cash flow	3.10	4.18	3.09	3.12	2.15	3.37	5.38	3.58	3.61	6.22
	Capex	(1.42)	(1.37)	(2.25)	(0.63)	(0.69)	(1.85)	(3.74)	(0.72)	(0.32)	(0.67)
	Free cash flow	1.68	2.81	0.84	2.49	1.45	1.52	1.64	2.87	3.29	5.55
	Book value	14.35	14.26	12.96	11.58	14.43	14.68	16.11	18.93	16.31	16.88
	Shares, m	52	53	52	51	51	51	51	51	50	47
Valuation, ×
Valuation, ×	P/E	0.00	83.91	85.48	66.00	71.16	75.26	36.78	37.03	19.03	27.76
	P/S	2.36	4.21	4.78	5.11	6.46	3.25	3.60	3.28	2.35	1.99
	P/B	2.83	5.06	6.93	8.60	7.69	4.31	5.14	4.48	3.90	3.34
	EV/Sales	2.49	4.08	4.94	5.28	7.04	3.55	4.00	3.76	2.80	2.72
	EV/FCF	25.51	24.85	110.78	41.35	83.24	45.35	56.06	33.82	23.01	13.88
Cash, $m
Cash, $m	Operating cash flow	160	220	159	158	109	172	273	182	182	293
	Capex	(73)	(72)	(116)	(32)	(35)	(94)	(190)	(36)	(16)	(31)
	Free cash flow	86	148	43	126	74	78	83	145	166	262
Balance, $m
Balance, $m	Working capital	299	136	340	329	440	314	518	469	357	552
	Total debt	254	59	322	306	691	559	754	798	921	1,220
	Net debt	114	(121)	153	168	498	300	470	619	614	974
	Shareholders’ equity	740	752	668	587	732	749	818	960	821	796
Returns, %
Returns, %	ROA	(2.05)	3.68	4.38	6.02	5.15	2.36	6.08	5.69	7.22	4.02
	ROIC	(1.42)	5.56	6.36	8.55	4.56	4.81	7.57	6.53	9.66	5.53
	ROE	(3.60)	6.11	7.75	12.20	12.05	5.86	14.72	13.22	18.83	12.03

Negative figures in brackets.

All 10 years →

Fiscal years to Mar 2026 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
BIO.B Bio-Rad Laboratories, Inc.	$10.3B	43.7×	—	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
GKOS Glaukos Corporation	$9.8B	— (loss-making)	— (loss-making)	+49.54% (above 0%: growing)	n/m	+211.83% (above 0%: growing)	81.67%	(9.30%)	Compare
BIO Bio-Rad Laboratories, Inc.	$9.8B	42.5×	35.4×	−0.09% (below 0%: shrinking)	+19.02% (above 0%: growing)	−6.06% (below 0%: shrinking)	53.12%	11.15%	Compare
PODD Insulet Corporation	$9.6B	26.4×	24.7×	+23.51% (above 0%: growing)	+328.13% (above 0%: growing)	−70.51% (below 0%: shrinking)	70.18%	16.18%	Compare
BRKR Bruker Corporation	$8.6B	— (loss-making)	55.7×	+5.15% (above 0%: growing)	n/m	+28.63% (above 0%: growing)	49.61%	(7.79%)	Compare
HAE Haemonetics Corporation	$5.5B	57.7×	18.0×	+5.60% (above 0%: growing)	+2.86% (above 0%: growing)	+220.38% (above 0%: growing)	59.76%	16.93%
LIVN LivaNova PLC	$4.3B	22.5×	26.0×	+10.80% (above 0%: growing)	+296.00% (above 0%: growing)	−26.66% (below 0%: shrinking)	70.07%	12.67%	Compare
ITGR Integer Holdings Corporation	$4.3B	34.3×	27.6×	−2.60% (below 0%: shrinking)	−34.91% (below 0%: shrinking)	+48.81% (above 0%: growing)	24.34%	7.44%	Compare
IRTC iRhythm Holdings, Inc.	$3.6B	— (loss-making)	— (loss-making)	+20.08% (above 0%: growing)	n/m	+116.98% (above 0%: growing)	72.80%	(1.13%)	Compare
Median of peers	$9.1B	34.3×	27.6×	+7.98%	+19.02%	+11.29%	61.60%	9.30%

All 149 Medical Devices stocks →

Haemonetics Corporation (HAE) key facts

Concern: Haemonetics Corporation’s revenue for fiscal 2026 (year ended March 2026) was $1.3 billion, down 1.97% from fiscal 2025.
Haemonetics Corporation (HAE) is a Medical Devices company in the Healthcare sector, listed on the New York Stock Exchange.
As of October 16, 2026, HAE traded at $118.28, a market capitalization of $5.5 billion.
Return on equity was 12.0% and debt-to-equity 1.40.
Its Piotroski F-score is 6 out of 9 and its Altman Z-score is 2.21 (grey zone) for fiscal 2026.

Source: company filings (standardised) and stockrow calculations.